FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198372272> ?p ?o ?g. }

• W3198372272 endingPage "4139" @default.
• W3198372272 startingPage "4125" @default.
• W3198372272 abstract "Antiapoptotic Bcl-2 family members have recently (re)emerged as key drug targets in cancer, with a tissue- and tumor-specific activity profile of available BH3 mimetics. In multiple myeloma, MCL-1 has been described as a major gatekeeper of apoptosis. This discovery has led to the rapid establishment of clinical trials evaluating the impact of various MCL-1 inhibitors. However, our understanding about the clinical impact and optimal use of MCL-1 inhibitors is still limited. We therefore explored mechanisms of acquired MCL-1 inhibitor resistance and optimization strategies in myeloma. Our findings indicated heterogeneous paths to resistance involving baseline Bcl-2 family alterations of proapoptotic (BAK, BAX, and BIM) and antiapoptotic (Bcl-2 and MCL-1) proteins. These manifestations depend on the BH3 profile of parental cells that guide the enhanced formation of Bcl-2:BIM and/or the dynamic (ie, treatment-induced) formation of Bcl-xL:BIM and Bcl-xL:BAK complexes. Accordingly, an unbiased high-throughput drug-screening approach (n = 528) indicated alternative BH3 mimetics as top combination partners for MCL-1 inhibitors in sensitive and resistant cells (Bcl-xL>Bcl-2 inhibition), whereas established drug classes were mainly antagonistic (eg, antimitotic agents). We also revealed reduced activity of MCL-1 inhibitors in the presence of stromal support as a drug-class effect that was overcome by concurrent Bcl-xL or Bcl-2 inhibition. Finally, we demonstrated heterogeneous Bcl-2 family deregulation and MCL-1 inhibitor cross-resistance in carfilzomib-resistant cells, a phenomenon linked to the MDR1-driven drug efflux of MCL-1 inhibitors. The implications of our findings for clinical practice emphasize the need for patient-adapted treatment protocols, with the tracking of tumor- and/or clone-specific adaptations in response to MCL-1 inhibition." @default.
• W3198372272 created "2021-09-13" @default.
• W3198372272 creator A5004122468 @default.
• W3198372272 creator A5005713464 @default.
• W3198372272 creator A5007815385 @default.
• W3198372272 creator A5010133593 @default.
• W3198372272 creator A5011779787 @default.
• W3198372272 creator A5016775133 @default.
• W3198372272 creator A5018939058 @default.
• W3198372272 creator A5028662013 @default.
• W3198372272 creator A5030239953 @default.
• W3198372272 creator A5038003121 @default.
• W3198372272 creator A5050763201 @default.
• W3198372272 creator A5054619375 @default.
• W3198372272 creator A5058034096 @default.
• W3198372272 creator A5058449477 @default.
• W3198372272 creator A5061939140 @default.
• W3198372272 creator A5069042392 @default.
• W3198372272 creator A5072157906 @default.
• W3198372272 creator A5083397767 @default.
• W3198372272 creator A5084485181 @default.
• W3198372272 creator A5087356462 @default.
• W3198372272 date "2021-10-21" @default.
• W3198372272 modified "2023-10-15" @default.
• W3198372272 title "Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma" @default.
• W3198372272 cites W1696775091 @default.
• W3198372272 cites W1933867057 @default.
• W3198372272 cites W1983470364 @default.
• W3198372272 cites W2011018672 @default.
• W3198372272 cites W2038745273 @default.
• W3198372272 cites W2049150145 @default.
• W3198372272 cites W2165294243 @default.
• W3198372272 cites W2291176625 @default.
• W3198372272 cites W2404356933 @default.
• W3198372272 cites W2410434383 @default.
• W3198372272 cites W2470668351 @default.
• W3198372272 cites W2485824342 @default.
• W3198372272 cites W2494443970 @default.
• W3198372272 cites W2510710599 @default.
• W3198372272 cites W2520922516 @default.
• W3198372272 cites W2534349779 @default.
• W3198372272 cites W2584063241 @default.
• W3198372272 cites W2605336808 @default.
• W3198372272 cites W2731995447 @default.
• W3198372272 cites W2746367132 @default.
• W3198372272 cites W2761234508 @default.
• W3198372272 cites W2794305966 @default.
• W3198372272 cites W2883591936 @default.
• W3198372272 cites W2892573863 @default.
• W3198372272 cites W2897811394 @default.
• W3198372272 cites W2904016068 @default.
• W3198372272 cites W2905070646 @default.
• W3198372272 cites W2912207391 @default.
• W3198372272 cites W2916031169 @default.
• W3198372272 cites W2926343247 @default.
• W3198372272 cites W2950182476 @default.
• W3198372272 cites W2951296099 @default.
• W3198372272 cites W2964193656 @default.
• W3198372272 cites W2974182987 @default.
• W3198372272 cites W2996593053 @default.
• W3198372272 cites W3009171874 @default.
• W3198372272 cites W3013744367 @default.
• W3198372272 cites W3021066042 @default.
• W3198372272 doi "https://doi.org/10.1182/bloodadvances.2020003826" @default.
• W3198372272 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34478517" @default.
• W3198372272 hasPublicationYear "2021" @default.
• W3198372272 type Work @default.
• W3198372272 sameAs 3198372272 @default.
• W3198372272 citedByCount "5" @default.
• W3198372272 countsByYear W31983722722022 @default.
• W3198372272 countsByYear W31983722722023 @default.
• W3198372272 crossrefType "journal-article" @default.
• W3198372272 hasAuthorship W3198372272A5004122468 @default.
• W3198372272 hasAuthorship W3198372272A5005713464 @default.
• W3198372272 hasAuthorship W3198372272A5007815385 @default.
• W3198372272 hasAuthorship W3198372272A5010133593 @default.
• W3198372272 hasAuthorship W3198372272A5011779787 @default.
• W3198372272 hasAuthorship W3198372272A5016775133 @default.
• W3198372272 hasAuthorship W3198372272A5018939058 @default.
• W3198372272 hasAuthorship W3198372272A5028662013 @default.
• W3198372272 hasAuthorship W3198372272A5030239953 @default.
• W3198372272 hasAuthorship W3198372272A5038003121 @default.
• W3198372272 hasAuthorship W3198372272A5050763201 @default.
• W3198372272 hasAuthorship W3198372272A5054619375 @default.
• W3198372272 hasAuthorship W3198372272A5058034096 @default.
• W3198372272 hasAuthorship W3198372272A5058449477 @default.
• W3198372272 hasAuthorship W3198372272A5061939140 @default.
• W3198372272 hasAuthorship W3198372272A5069042392 @default.
• W3198372272 hasAuthorship W3198372272A5072157906 @default.
• W3198372272 hasAuthorship W3198372272A5083397767 @default.
• W3198372272 hasAuthorship W3198372272A5084485181 @default.
• W3198372272 hasAuthorship W3198372272A5087356462 @default.
• W3198372272 hasBestOaLocation W31983722721 @default.
• W3198372272 hasConcept C104317684 @default.
• W3198372272 hasConcept C114851261 @default.
• W3198372272 hasConcept C149011108 @default.
• W3198372272 hasConcept C149150037 @default.
• W3198372272 hasConcept C16930146 @default.

• next